Athira Pharma Inc

For the period ended Dec 31, 2024. Filed Feb 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 27, 2025

LONA$4.02-10.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders' Equity

(in thousands, except share amounts)

Accumulated
Common Stock · AdditionalPaid-In · OtherComprehensive · Accumulated · TotalStockholders’
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance as of January 1, 2023	37,877,387	$4	$428,623	$(1,956)	$(191,534)	$235,137
Issuance of common stock upon exercise of common stock options	128,534	—	167	—	—	167
Issuance of common stock under employee stock purchase plan	166,682	—	326	—	—	326
Stock-based compensation	—	—	10,623	—	—	10,623
Unrealized gain on available-for-sale securities	—	—	—	1,607	—	1,607
Net loss	—	—	—	—	(117,672)	(117,672)
Balance as of December 31, 2023	38,172,603	$4	$439,739	$(349)	$(309,206)	$130,188
Issuance of common stock upon exercise of common stock options	75,660	—	12	—	—	12
Issuance of common stock upon vesting of restricted stock units	620,668	—	—	—	—	—
Issuance of common stock under employee stock purchase plan	172,014	—	182	—	—	182
Stock-based compensation	—	—	11,049	—	—	11,049
Unrealized gain on available-for-sale securities	—	—	—	350	—	350
Net loss	—	—	—	—	(96,940)	(96,940)
Balance as of December 31, 2024	39,040,945	$4	$450,982	$1	$(406,146)	$44,841

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.